Evidence map›Paper›PMID 35145189›Full record

Observational studyScientific reports2022

Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort.

Brent Appelman, Jetta J Oppelaar, Lani Broeders, Willem Joost Wiersinga, Hessel Peters-Sengers, Liffert Vogt, CovidPredict Study Group

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  19. Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 12 institutions in 1 country.

Brent AppelmanCenter for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Jetta J OppelaarDepartment of Internal Medicine, Section of Nephrology, Amsterdam UMC, Amsterdam, The Netherlands.
Lani BroedersDepartment of Internal Medicine, Section of Nephrology, Amsterdam UMC, Amsterdam, The Netherlands.
Willem Joost WiersingaCenter for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Hessel Peters-SengersCenter for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Liffert VogtDepartment of Internal Medicine, Section of Nephrology, Amsterdam UMC, Amsterdam, The Netherlands. l.vogt@amsterdamumc.nl.
CovidPredict Study Group
Amsterdam University Medical Centers · NLAmsterdam UMC Location University of Amsterdam · NLNoordwest Ziekenhuisgroep · NLAmsterdam Neuroscience · NLFlevoziekenhuis · NLMaastricht University Medical Centre · NLMartini Ziekenhuis · NLOLVG · NLSt. Antonius Ziekenhuis · NLTreant Zorggroep · NLVieCuri Medisch Centrum · NLZuyderland Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.

Indexed as

AgedCOVID-19FemaleHumansMaleMiddle AgedNetherlandsPatient ReadmissionRenal Insufficiency, ChronicRetrospective StudiesRisk Factors

Identifiers

PMID35145189
PMCPMC8831646
OpenAlexW4211160492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.